US Patent Issued to Ablynx, Sanofi on Dec. 9 for "Methods of treatment utilizing polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP" (Belgian, German, American Inventors)

ALEXANDRIA, Va., Dec. 9 -- United States Patent no. 12,492,248, issued on Dec. 9, was assigned to Ablynx N.V. (Ghent-Zwijnaarde, Belgium) and Sanofi (Paris).

"Methods of treatment utilizing polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP" was invented by Heidi Rommelaere (Ghent, Belgium), Ann Brige (Ertvelde, Belgium), Sigrid Cornelis (St. Martens-Latem, Belgium), Bruno Dombrecht (Heusden, Belgium), Eric Lorent (Zwijnaarde, Belgium), Melanie Rieger (Zwijnaarde, Belgium), Timothy Soos (Bridgewater, N.J.), John Park (Warthausen, Germany), Bernd Weigle (Ingelheim am Rhein, Germany) and Klaus Erb (Ingelheim am Rhein, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "T...